Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation.
Hematopoietic stem cell transplantation from a healthy donor (allo-HSCT) represents the most potent form of cellular adoptive immunotherapy to treat malignancies. In allo-HSCT, donor T cells are double edge-swords: highly potent against residual tumor cells, but potentially highly toxic, and responsible for graft versus host disease (GVHD), a major clinical complication of transplantation. Gene transfer technologies coupled with current knowledge on cancer immunology have generated a wide range of approaches aimed at fostering the immunological response to cancer cells, while avoiding or controlling GVHD. In this review, we discuss cell and gene therapy approaches currently tested in preclinical models and in clinical trials.
['Cieri|Nicoletta|N|', 'Mastaglio|Sara|S|', 'Oliveira|Giacomo|G|', 'Casucci|Monica|M|', 'Bondanza|Attilio|A|', 'Bonini|Chiara|C|']
D000818:Animals D060833:Cellular Microenvironment D018014:Gene Transfer Techniques D005818:Genetic Engineering D015316:Genetic Therapy D006086:Graft vs Host Disease D018380:Hematopoietic Stem Cell Transplantation D006801:Humans D016219:Immunotherapy, Adoptive D009369:Neoplasms D011948:Receptors, Antigen, T-Cell D013601:T-Lymphocytes D014161:Transduction, Genetic D014184:Transplantation, Homologous
gene therapy CAR TCR adoptive cellular immunotherapy allogeneic hematopoietic stem cell transplantation suicide gene